Loading...
Market
What will be the most significant outcome of the Massive Bio and Foundation Medicine partnership by end of 2025?
2
Resolution / Starting Odds
Increased clinical trial enrollment • 25%
New AI-driven clinical trial • 25%
New FDA-approved treatment • 25%
Other • 25%
Official announcements, industry reports, or scientific publications
Story
Massive Bio Partners with Foundation Medicine to Improve Cancer Clinical Trials at ESMO24
Sep 13, 2024, 12:09 PM
Biotech company Massive Bio has announced a partnership with Foundation Medicine to enhance clinical trial recruitment and enrollment, focusing on precision cancer care. The collaboration aims to address the low enrollment rates in cancer clinical trials by leveraging AI and genomic profiling. This partnership, highlighted at the ESMO24 conference, is seen as a pivotal step in developing solutions to the cancer clinical trial enrollment paradox, potentially allowing more patients to access advanced treatments.
View original story
Similar markets
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
ADHD • 25%
Schizophrenia • 25%
Bipolar Disorder • 25%
Parkinson’s Disease • 25%
Significant cost reduction • 25%
Faster drug development • 25%
Increased collaboration with AI companies • 25%
All of the above • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Johnson & Johnson • 25%
Novartis • 25%
Other • 25%
Full agreement executed • 25%
Partial execution • 25%
Agreement terminated • 25%
No significant progress • 25%
Technology development for surgeons • 25%
Cancer screenings • 25%
Follow-up treatments • 25%
Other • 25%
Tumor-removal technologies • 25%
Cancer screening and early detection • 25%
Cancer treatment in underserved communities • 25%
Other • 25%
Illumina • 25%
Thermo Fisher Scientific • 25%
Pacific Biosciences • 25%
Other • 25%
Genetic Testing • 25%
Health and Wellness • 25%
Data Licensing • 25%
Other • 25%